Aprepitant versus dexamethasone for delayed emesis: What is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?

Journal of Clinical Oncology

Volumn 32, Issue 20, 2014, Pages 2185-2186

  Celio, Luigi ^a   De Braud, Filippo ^a   Aapro, Matti ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANISETRON; ONDANSETRON; PALONOSETRON;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DELAYED EMESIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MORPHOLINES; VOMITING;

EID: 84905822381     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.4352     Document Type: Letter

References (8)

1. Roila F, Ruggeri B, Ballatori E, et al: Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: A randomized double-blind study. J Clin Oncol 32:101-106, 2014
2. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005 (Pubitemid 46179473)
3. Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124, 2009
4. Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
5. Aapro MS, Rossi G, Rizzi G, et al: Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC). J Clin Oncol 31:578s, 2013 (suppl; abstr LBA9514)
6. Celio L, Bonizzoni E, Bajetta E, et al: Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 21:565-573, 2013
7. Roila F, Herrstedt J, Aapro M, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 21:v232-v243, 2010 (suppl 5)
8. Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189-4198, 2011